1 pixel 1 empty pixel
Edesa Biotech announcement

Canada to invest $23 million in Markham-based Edesa Biotech

This groundbreaking project aligns with Canada's Biomanufacturing and Life Sciences Strategy and will support increased innovation, as well as world-class expertise and infrastructure for clinical trials.
Edesa Biotech announcement

The Government of Canada is working tirelessly to rebuild Canada’s domestic biomanufacturing sector to develop safe and efficient treatments for Canadians.

The Honourable Mary Ng, Minister of Export Promotion, International Trade and Economic Development, announced a contribution of $23 million to support Edesa Biotech’s $61 million project through the Strategic Innovation Fund (SIF). Edesa is a biopharmaceutical company based in Markham, Ontario, that is seeking to advance Phase III clinical trials for its monoclonal antibody therapy (EB05), for the treatment of acute respiratory distress syndrome (ARDS) in COVID-19 patients. 

Full Article: newswire.ca